The role of salivary neuropeptides in pediatrics

Potential biomarkers for integrated therapies

Lynn A. Gershan, Paul L. Durham, Jaci Skidmore, Joshua Shimizu, Ryan J. Cady, Xiaoming Sheng, Christopher G Maloney

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Objective measures of symptom response to integrated complementary approaches in pediatrics are evolving. The purpose of this study was to document the concentration range of salivary neuropeptides in healthy controls and in children with cancer, to explore correlations between serum and salivary measurements for calcitonin gene-related peptide (CGRP) and vasoactive intestinal polypeptide (VIP), and to determine whether there is a change in these salivary neuropeptide levels in response to integrated mind-body therapies. Methods: A non-randomized pragmatic study with three phases: Phase 1-healthy control saliva-10 healthy controls provided saliva samples; Phase 2-cancer diagnosis serum-saliva-16 mixed-type cancer patients provided blood and saliva samples; Phase 3-acute lymphocytic leukemia (ALL) saliva intervention-12 patients with ALL provided pre- and post-complementary intervention saliva samples. Interventions: 20. min of structured touch or scripted relaxation breathing were administered to patients in Phase 3; Phase 1 and 2 patients did not receive this intervention. Outcome Measures: cortisol, CGRP, VIP, Sate-Trait Anxiety Inventory, visual analogue scale, vital signs. Results: Salivary CGRP and VIP were similar for children in Phases 1 and 2. There was a correlation between serum and salivary VIP in the mixed cancer group, though not between serum and salivary CGRP. In Phase 3 children, following a complementary intervention, salivary CGRP, heart rate, and systolic blood pressure decreased. Conclusions: These data provide evidence of a decrease in sympathetic output after integrative/complementary therapy intervention in children with cancer. The study underscores the potential role of salivary neuropeptides as non-invasive biomarkers for integrated therapies in pediatrics.

Original languageEnglish (US)
Pages (from-to)372-377
Number of pages6
JournalEuropean Journal of Integrative Medicine
Volume7
Issue number4
DOIs
StatePublished - Aug 1 2015

Fingerprint

Neuropeptides
Saliva
Calcitonin Gene-Related Peptide
Biomarkers
Vasoactive Intestinal Peptide
Pediatrics
Salivary Proteins and Peptides
Neoplasms
Serum
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mind-Body Therapies
Therapeutics
Blood Pressure
Vital Signs
Touch
Complementary Therapies
Visual Analog Scale
Hydrocortisone
Respiration
Anxiety

Keywords

  • Autonomic nervous system
  • Biomarker
  • Complementary therapy
  • Integrated therapy
  • Salivary neuropeptide

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

The role of salivary neuropeptides in pediatrics : Potential biomarkers for integrated therapies. / Gershan, Lynn A.; Durham, Paul L.; Skidmore, Jaci; Shimizu, Joshua; Cady, Ryan J.; Sheng, Xiaoming; Maloney, Christopher G.

In: European Journal of Integrative Medicine, Vol. 7, No. 4, 01.08.2015, p. 372-377.

Research output: Contribution to journalArticle

Gershan, Lynn A. ; Durham, Paul L. ; Skidmore, Jaci ; Shimizu, Joshua ; Cady, Ryan J. ; Sheng, Xiaoming ; Maloney, Christopher G. / The role of salivary neuropeptides in pediatrics : Potential biomarkers for integrated therapies. In: European Journal of Integrative Medicine. 2015 ; Vol. 7, No. 4. pp. 372-377.
@article{864986e8f3fe473a955dfebe93c0d8e3,
title = "The role of salivary neuropeptides in pediatrics: Potential biomarkers for integrated therapies",
abstract = "Introduction: Objective measures of symptom response to integrated complementary approaches in pediatrics are evolving. The purpose of this study was to document the concentration range of salivary neuropeptides in healthy controls and in children with cancer, to explore correlations between serum and salivary measurements for calcitonin gene-related peptide (CGRP) and vasoactive intestinal polypeptide (VIP), and to determine whether there is a change in these salivary neuropeptide levels in response to integrated mind-body therapies. Methods: A non-randomized pragmatic study with three phases: Phase 1-healthy control saliva-10 healthy controls provided saliva samples; Phase 2-cancer diagnosis serum-saliva-16 mixed-type cancer patients provided blood and saliva samples; Phase 3-acute lymphocytic leukemia (ALL) saliva intervention-12 patients with ALL provided pre- and post-complementary intervention saliva samples. Interventions: 20. min of structured touch or scripted relaxation breathing were administered to patients in Phase 3; Phase 1 and 2 patients did not receive this intervention. Outcome Measures: cortisol, CGRP, VIP, Sate-Trait Anxiety Inventory, visual analogue scale, vital signs. Results: Salivary CGRP and VIP were similar for children in Phases 1 and 2. There was a correlation between serum and salivary VIP in the mixed cancer group, though not between serum and salivary CGRP. In Phase 3 children, following a complementary intervention, salivary CGRP, heart rate, and systolic blood pressure decreased. Conclusions: These data provide evidence of a decrease in sympathetic output after integrative/complementary therapy intervention in children with cancer. The study underscores the potential role of salivary neuropeptides as non-invasive biomarkers for integrated therapies in pediatrics.",
keywords = "Autonomic nervous system, Biomarker, Complementary therapy, Integrated therapy, Salivary neuropeptide",
author = "Gershan, {Lynn A.} and Durham, {Paul L.} and Jaci Skidmore and Joshua Shimizu and Cady, {Ryan J.} and Xiaoming Sheng and Maloney, {Christopher G}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.eujim.2015.06.001",
language = "English (US)",
volume = "7",
pages = "372--377",
journal = "European Journal of Integrative Medicine",
issn = "1876-3820",
publisher = "Elsevier GmbH",
number = "4",

}

TY - JOUR

T1 - The role of salivary neuropeptides in pediatrics

T2 - Potential biomarkers for integrated therapies

AU - Gershan, Lynn A.

AU - Durham, Paul L.

AU - Skidmore, Jaci

AU - Shimizu, Joshua

AU - Cady, Ryan J.

AU - Sheng, Xiaoming

AU - Maloney, Christopher G

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Introduction: Objective measures of symptom response to integrated complementary approaches in pediatrics are evolving. The purpose of this study was to document the concentration range of salivary neuropeptides in healthy controls and in children with cancer, to explore correlations between serum and salivary measurements for calcitonin gene-related peptide (CGRP) and vasoactive intestinal polypeptide (VIP), and to determine whether there is a change in these salivary neuropeptide levels in response to integrated mind-body therapies. Methods: A non-randomized pragmatic study with three phases: Phase 1-healthy control saliva-10 healthy controls provided saliva samples; Phase 2-cancer diagnosis serum-saliva-16 mixed-type cancer patients provided blood and saliva samples; Phase 3-acute lymphocytic leukemia (ALL) saliva intervention-12 patients with ALL provided pre- and post-complementary intervention saliva samples. Interventions: 20. min of structured touch or scripted relaxation breathing were administered to patients in Phase 3; Phase 1 and 2 patients did not receive this intervention. Outcome Measures: cortisol, CGRP, VIP, Sate-Trait Anxiety Inventory, visual analogue scale, vital signs. Results: Salivary CGRP and VIP were similar for children in Phases 1 and 2. There was a correlation between serum and salivary VIP in the mixed cancer group, though not between serum and salivary CGRP. In Phase 3 children, following a complementary intervention, salivary CGRP, heart rate, and systolic blood pressure decreased. Conclusions: These data provide evidence of a decrease in sympathetic output after integrative/complementary therapy intervention in children with cancer. The study underscores the potential role of salivary neuropeptides as non-invasive biomarkers for integrated therapies in pediatrics.

AB - Introduction: Objective measures of symptom response to integrated complementary approaches in pediatrics are evolving. The purpose of this study was to document the concentration range of salivary neuropeptides in healthy controls and in children with cancer, to explore correlations between serum and salivary measurements for calcitonin gene-related peptide (CGRP) and vasoactive intestinal polypeptide (VIP), and to determine whether there is a change in these salivary neuropeptide levels in response to integrated mind-body therapies. Methods: A non-randomized pragmatic study with three phases: Phase 1-healthy control saliva-10 healthy controls provided saliva samples; Phase 2-cancer diagnosis serum-saliva-16 mixed-type cancer patients provided blood and saliva samples; Phase 3-acute lymphocytic leukemia (ALL) saliva intervention-12 patients with ALL provided pre- and post-complementary intervention saliva samples. Interventions: 20. min of structured touch or scripted relaxation breathing were administered to patients in Phase 3; Phase 1 and 2 patients did not receive this intervention. Outcome Measures: cortisol, CGRP, VIP, Sate-Trait Anxiety Inventory, visual analogue scale, vital signs. Results: Salivary CGRP and VIP were similar for children in Phases 1 and 2. There was a correlation between serum and salivary VIP in the mixed cancer group, though not between serum and salivary CGRP. In Phase 3 children, following a complementary intervention, salivary CGRP, heart rate, and systolic blood pressure decreased. Conclusions: These data provide evidence of a decrease in sympathetic output after integrative/complementary therapy intervention in children with cancer. The study underscores the potential role of salivary neuropeptides as non-invasive biomarkers for integrated therapies in pediatrics.

KW - Autonomic nervous system

KW - Biomarker

KW - Complementary therapy

KW - Integrated therapy

KW - Salivary neuropeptide

UR - http://www.scopus.com/inward/record.url?scp=84941260405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941260405&partnerID=8YFLogxK

U2 - 10.1016/j.eujim.2015.06.001

DO - 10.1016/j.eujim.2015.06.001

M3 - Article

VL - 7

SP - 372

EP - 377

JO - European Journal of Integrative Medicine

JF - European Journal of Integrative Medicine

SN - 1876-3820

IS - 4

ER -